Skip to search formSkip to main contentSkip to account menu

ALN-PCSsc

Known as: inclisiran 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
INCLISIRAN AND CARDIOVASCULAR OUTCOMES: ANALYSES FROM ORION-11
2020
2020
UK deal over inclisiran
Government’s public enthusiasm looks premature given the lack of available data 
2020
2020
Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia.
2020
2020
EVALUATION OF LDL-C REDUCTIONS BY SIRNA TREATMENT WITH INCLISIRAN IN PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME OR NEITHER
2019
2019
Inclisiran Durably Lowers Ldl-C And Pcsk9 Expression In Subjects With Homozygous Familial Hypercholesterolaemia: The Orion-2 Pilot Study
Review
2019
Review
2019
Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
PURPOSE OF REVIEW The use of therapeutic monoclonal antibodies to target proprotein convertase subtilisin/kexin type 9 (PCSK9… 
2019
2019
PCSK9-lowering RNAi contender clears first phase III trial
2019
2019
Efficacy, Safety And Pharmacokinetics Of Inclisiran By Renal Function
2017
2017
Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol.
  • A. Slomski
  • Journal of the American Medical Association (JAMA…
  • 2017
  • Corpus ID: 37165162
In a trial published recently in the New England Journal of Medicine (NEJM), evolocumab, a monoclonal antibody that inhibits… 
Review
2017
Review
2017
PCSK9 Inhibition-Reaching Physiologic LDL-C Levels “Endo, Goldstein and Brown’s Dream is Coming True”
  • M. Ec
  • 2017
  • Corpus ID: 21742619
Physiologically, in the presence of an intracellular deficit of cholesterol, the LDLR synthesis, expression and function… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)